FORT COLLINS, Colo., May 17 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. today announced that it will present at the 2004 UBS Global Specialty Pharmaceuticals Conference May 24, 2004 at 10:00 a.m. EDT.
There will be a live webcast of the presentation from the conference. The webcast will be accessible through a link posted on the Atrix website home page at http://www.atrixlabs.com/. The presentation will also be available for replay on Atrix's website for a limited period of time after the conference.
Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With unique patented sustained release and topical technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products. Additional information is available on the Atrix Laboratories, Inc. website at http://www.atrixlabs.com/
Statements made at the conference, which are not historical facts, are forward-looking statements, as the term is defined under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties which may cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, risks associated with product demand, pricing, market acceptance of its current and proposed products, changing economic conditions, risks in product and technology development, and competition from other products and treatments. For additional information about risk factors, please see the reports filed by the company with the SEC, including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 and the company's Annual Report on Form 10-K for the year ended December 31, 2003. All forward-looking statements in this press release are made as of the date hereof, based on information available to the company as of the date hereof, and the company assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
Atrix Laboratories, Inc.CONTACT: Danette R.M. Meyer, Ph.D., Director, Investor Relations ofAtrix Laboratories, Inc., +1-970-482-5868, Dmeyer@atrixlab.com
Web site: http://www.atrixlabs.com/